Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04971772
Other study ID # FCRE-210621
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date June 8, 2022
Est. completion date May 2026

Study information

Verified date February 2023
Source Cardionovum GmbH
Contact Sabrina Overhagen, Dr.
Phone +4915780591411
Email info@fcre.eu
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The aim of this study is to demonstrate the superiority in safety and efficacy of the Legflow DCB vs standard uncoated POBA in a randomized controlled (RCT) for treatment of patients with symptomatic peripheral artery disease (PAD) due to stenosis, restenosis or occlusion of the femoral and/or popliteal arteries.


Recruitment information / eligibility

Status Recruiting
Enrollment 148
Est. completion date May 2026
Est. primary completion date May 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion criteria - Patient is =18 years - Patient has Rutherford Classification 2,3 or4. - Patient has provided written informed consent and is willing to comply with study follow-up requirements. - De novo stenotic or occlusive lesion(s) or non-stented restenotic or occlusive lesion(s) occurring >90 days after prior plain old balloon (POBA) angioplasty or >180 days after prior DCB treatment. - Target lesion is located between the ostium of the SFA and the end of the P1 segment of the popliteal artery - Target vessel diameter = 4 mm and = 7 mm - Target lesion must be stenotic or occlusive lesion = 150mm in length (one long lesion or tandem lesions) by investigator's visual estimate. [Note: tandem lesions must have a total length of = 150 mm by visual estimate and be separated by = 30 mm.] - Target lesion must have angiographic evidence of = 70 % stenosis by investigator's visual estimation - Successful, uncomplicated crossing of the target lesion occurs when the tip of the guidewire is distal to the target lesion without the occurrence of flow-limiting dissection of perforation and is judged by visual inspection to be within the true lumen. Subintimal dissection techniques may be used if re-entry occurs above-the-knee (ATK) and without the use of re-entry devices. - Target lesion is located at least 30mm from any stent if target vessel was previously stented. - A patent inflow artery free from significant stenosis ((=50% stenosis) as confirmed by angiography. - At least one patent native outflow artery to the ankle or foot, free from significant stenosis (= 50 % stenosis) as confirmed by angiography. Exclusion criteria: - Acute Limb Ischemia - Patient underwent an intervention involving the target vessel within the previous 90 days. - Patient underwent any lower extremity percutaneous treatment in the ipsilateral limb using plain old balloon (POBA) angioplasty within the previous 90 days. - Patient underwent a percutaneous transluminal angioplasty (PTA) of the target lesion using a DCB within the previous 180 days. - Pregnant women or women who are intending to become pregnant. - Patient has a life expectancy of less than 1 year - Patient has a known allergy to contrast medium that cannot be adequately pre-medicated. - Patient is allergic to all anti-platelet treatments - Patient is receiving immunosuppressant therapy - Patient has platelet count <100.000/mm3 or >700.000/mm - Patient has history of gastrointestinal hemorrhage requiring a transfusion within 3 months prior to the study procedure - Patient is diagnosed with coagulopathy that precludes treatment with systemic anticoagulation and/or dual antiplatelet therapy (DAPT) - Patient has history of stroke within past 90 days - Patient has history of myocardial infarction within the past 30 days. - Patient is participating in an investigational drug or medical device study that has not completed primary endpoint(s) evaluation or that clinically interferes with the endpoints from this study. - Patient has had any major (e.g. cardiac, peripheral, abdominal) surgical procedure or intervention unrelated to this study within 30 days prior to the index procedure or has planned major surgical procedure or intervention within 30 days of the index procedure - An intervention in the contralateral limb, planned within 30 days post-index procedure - Patient had previous bypass surgery of the target lesion - Patient had previous treatment of the target vessel with thrombolysis or surgery - Patient is unwilling or unable to comply with procedures specified in the protocol or has difficulty or inability to return for follow-up visits as specified by the protocol - Target lesion involves an aneurysm or is adjacent to an aneurysm (within 5 mm) - Target Lesion requires treatment with alternative therapy such as stenting, laser, atherectomy, cryoplasty, brachytherapy or re-entry devices - Significant target vessel tortuosity or other parameters prohibiting access to the target lesion - Presence of thrombus in the target vessel - Iliac inflow disease requiring treatment, unless the iliac artery disease is successfully treated first during the index procedure. Success is defined as = 30 % residual diameter stenosis without death or major complications. - Presence of an aortic, iliac or femoral artificial graft.

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
Germany Sankt Gertrauden-Krankenhaus Berlin Berlin
Germany Medizinisches Versorgungszentrum Prof. Mathey, Prof. Schofer GmbH Hamburg
Germany Universitätsklinikum Heidelberg Heidelberg
Germany SRH Klinikum Karlsbad-Langenseinbach GmbH Karlsbad
Germany St. Franziskus-Hospital GmbH Münster
Germany GRN-Klinik Weinheim Weinheim

Sponsors (2)

Lead Sponsor Collaborator
Cardionovum GmbH FCRE (Foundation for Cardiovascular Research and Education)

Country where clinical trial is conducted

Germany, 

Outcome

Type Measure Description Time frame Safety issue
Primary Primary Efficacy Endpoint: The primary efficacy endpoint is time to clinically-driven target lesion revascularization (CD-TLR) at 12 months, defined as any reintervention at the target lesion due to symptoms OR drop of ankle brachial index (ABI) > 20 % OR ABI > 0.15 compared to the post-procedural ABI. 12 months post-procedure
Primary Device- and procedure-related death Primary Safety Endpoint:
Freedom from device- and procedure-related death through 30 days post-index procedure;
30 days post-procedure
Primary Major target limb amputation and clinically-driven target vessel revascularization Primary Safety Endpoint:
A composite of (2.1) time to major target limb amputation (above-the-ankle (ATA)) through 12 months post-procedure and (2.2) time to clinically-driven target vessel revascularization (CD-TVR) through 12 months post-index procedure
12 months post-procedure
Secondary Acute device success defined as successful delivery, balloon inflation, deflation and retrieval of the intact study device without burst below rated burst pressure during index procedure
Secondary Acute procedural success Acute procedural success is defined as restoration of the target lesion with =30% residual stenosis in the final angiogram. during index procedure
Secondary Secondary safety endpoint at discharge up to 30 days post-index procedure Secondary safety endpoint is a composite of (3.1) freedom from all cause death (3.2) freedom from major target limb amputation (3.3) freedom from CD-TVR 30 days post-operative
Secondary Sustained clinical improvement at 6-, 12- and 24- months post-index procedure Clinical improvement is defined as a composite of (4.1) freedom from major target limb amputation, (4.2) freedom from TVR, (4.3) freedom from worsening target limb Rutherford class (compared to baseline) (4.4) freedom from decrease in target limb ankle brachial index (ABI) =0.15 (compared to baseline) 6, 12, 24-months post-procedure
Secondary Major Adverse Events (MAEs) at 6-, 12- and 24-months post-index procedure MAEs are defined as composite of (5.1) all-cause death, (5.2) CD-TVR (5.3) major target limb amputation (5.4) thrombosis at the target lesion 6, 12, 24-months post-procedure
Secondary Primary Patency at 6-, 12- and 24-months The primary patency is defined as a composite of (6.1) freedom from clinically-driven target lesion revascularization (CD-TLR)
(6.2) freedom from binary restenosis (restenosis defined as duplex ultrasound (DUS) peak systolic velocity ratio (PSVR) =2.4 or =50% stenosis)
• For discharge and 12-months: assessed by independent Core Lab
6, 12, 24-months post-procedure
Secondary Target Lesion Revascularization at 6-, 12- and 24-months post-index procedure defined as a reintervention to maintain or restore the patency in the target lesion. TLR is clinically-driven (CD) when the TLR was needed due to symptoms or drop of ankle brachial index (ABI) of =20% or >0.15 when compared to post-procedure. 6, 12, 24-months post-procedure
Secondary Target Vessel Revascularization at 6-, 12- and 24-months post-index procedure defined as a reintervention to maintain or restore the patency in the target vessel. TVR is clinically-driven (CD) when the TVR was needed due to symptoms or drop of ankle brachial index (ABI) of =20% or >0.15 when compared to post-procedure 6, 12, 24-months post-procedure
Secondary Binary restenosis at 6-, 12- and 24-months defined as a restenosis confirmed by DUS PSVR =2.4 or =50% stenosis (For 12-month: assessed by Independent Core-Lab) 6, 12, 24-months post-procedure
Secondary Major Target Limb Amputation at 6-, 12- and 24-months defined as an amputation above the ankle (ATA) in the target limb 30- days, 6, 12, 24-months post-procedure
Secondary Thrombosis at the target lesion at 6-, 12- and 24-months Thrombosis at the target lesion at 6-, 12- and 24-months 6, 12, 24-months post-procedure
Secondary All-cause death at 6-, 12- and 24-months All-cause death at 6-, 12- and 24-months 30- days, 6, 12, 24-months post-procedure
Secondary Change in target limb Rutherford Classification from baseline to 6-, 12- and 24-months Change in Target Limb Rutherford Classification from baseline to 6-, 12- and 24-months 6, 12, 24-months post-procedure
Secondary Change in Target Limb Resting ABI or TBI from baseline to 6-, 12- and 24-months Change in Target Limb Resting ABI or TBI from baseline to 6-, 12- and 24-months 6, 12, 24-months post-procedure
Secondary Improvement of life quality according to the Walking Impairment Questionnaire (WIQ) and the EQ-5D Questionnaire to baseline at follow-up at 6-, 12- and 24-month. Improvement of life quality according to the Walking Impairment Questionnaire (WIQ) and the EQ-5D Questionnaire to baseline at follow-up at 6-, 12- and 24-month. 6, 12, 24-months post-procedure
Secondary device- and procedure-related death Freedom from device- and procedure-related death at discharge, 30 days, 6-, 12- and 24-months 30- days, 6, 12, 24-months post-procedure
See also
  Status Clinical Trial Phase
Recruiting NCT06032065 - Sequential Multiple Assessment Randomized Trial of Exercise for PAD: SMART Exercise for PAD (SMART PAD) Phase 3
Active, not recruiting NCT03987061 - MOTIV Bioresorbable Scaffold in BTK Artery Disease N/A
Recruiting NCT03506633 - Impacts of Mitochondrial-targeted Antioxidant on Peripheral Artery Disease Patients N/A
Active, not recruiting NCT03506646 - Dietary Nitrate Supplementation and Thermoregulation N/A
Active, not recruiting NCT04677725 - NEtwork to Control ATherothrombosis (NEAT Registry)
Recruiting NCT05961943 - RESPONSE-2-PAD to Reduce Sedentary Time in Peripheral Arterial Disease Patients N/A
Recruiting NCT06047002 - Personalised Antiplatelet Therapy for Patients With Symptomatic Peripheral Arterial Disease
Completed NCT03185052 - Feasibility of Outpatient Care After Manual Compression in Patients Treated for Peripheral Arterial Disease by Endovascular Technique With 5F Sheath Femoral Approach N/A
Recruiting NCT05992896 - A Study of Loco-Regional Liposomal Bupivacaine Injection Phase 4
Completed NCT04635501 - AbsorbaSeal (ABS 5.6.7) Vascular Closure Device Trial N/A
Recruiting NCT04584632 - The Efemoral Vascular Scaffold System (EVSS) for the Treatment of Patients With Symptomatic Peripheral Vascular Disease From Stenosis or Occlusion of the Femoropopliteal Artery N/A
Withdrawn NCT03994185 - The Merit WRAPSODY™ Endovascular Stent Graft for Treatment of Iliac Artery Occlusive Disease N/A
Withdrawn NCT03538392 - Serranator® Alto Post Market Clinical Follow Up (PMCF) Study
Recruiting NCT02915796 - Autologous CD133(+) Cells as an Adjuvant to Below the Knee Percutaneous Transluminal Angioplasty Phase 1
Active, not recruiting NCT02900924 - Observational Study to Evaluate the BioMimics 3D Stent System: MIMICS-3D
Completed NCT02901847 - To Evaluate the Introduction of a Public Health Approach to Peripheral Arterial Disease (PAD) Using National Centre for Sport and Exercise Medicine Facilities. N/A
Withdrawn NCT02126540 - Trial of Pantheris System, an Atherectomy Device That Provides Imaging While Removing Plaque in Lower Extremity Arteries N/A
Not yet recruiting NCT02455726 - Magnesium Oral Supplementation to Reduce Pain Inpatients With Severe Peripheral Arterial Occlusive Disease N/A
Not yet recruiting NCT02387450 - Reduced Cardiovascular Morbi-mortality by Sildenafil in Patients With Arterial Claudication Phase 2/Phase 3
Completed NCT02022423 - Physical Activity Daily - An Internet-Based Walking Program for Patients With Peripheral Arterial Disease N/A